Two Sigma Investments
PRLD icon

Two Sigma Investments’s Prelude Therapeutics PRLD Stock Holding History

Two Sigma Investments’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.16M Buy
923,626
+134,931
+17% +$354K ﹤0.01% 2402
2025
Q4 		$2.29M Buy
788,695
+636,462
+418% +$1.07M ﹤0.01% 2334
2025
Q3 		$219K Sell
152,233
-2,744
-2% -$2.75K ﹤0.01% 3347
2025
Q2 		$125K Sell
154,977
-28,690
-16% -$24.8K ﹤0.01% 2977
2025
Q1 		$141K Sell
183,667
-48,172
-21% -$44.9K ﹤0.01% 2912
2024
Q4 		$296K Buy
231,839
+174,906
+307% +$232K ﹤0.01% 2741
2024
Q3 		$118K Buy
56,933
+13,798
+32% +$63.9K ﹤0.01% 2878
2024
Q2 		$164K Sell
43,135
-17,462
-29% -$71.1K ﹤0.01% 2765
2024
Q1 		$287K Buy
60,597
+2,313
+4% +$9K ﹤0.01% 2576
2023
Q4 		$249K Buy
58,284
+45,471
+355% +$138K ﹤0.01% 2758
2023
Q3 		$39.6K Sell
12,813
-26,477
-67% -$99.4K ﹤0.01% 2833
2023
Q2 		$177K Buy
39,290
+16,835
+75% +$101K ﹤0.01% 2668
2023
Q1 		$128K Sell
22,455
-29,443
-57% -$180K ﹤0.01% 2643
2022
Q4 		$313K Sell
51,898
-53,703
-51% -$344K ﹤0.01% 2222
2022
Q3 		$698K Sell
105,601
-118,235
-53% -$797K ﹤0.01% 1625
2022
Q2 		$1.17M Buy
223,836
+43,424
+24% +$221K ﹤0.01% 1478
2022
Q1 		$1.25M Sell
180,412
-102,362
-36% -$936K ﹤0.01% 1600
2021
Q4 		$3.52M Buy
+282,774
New +$4.6M 0.01% 1441
2021
Q3 		– Sell
-10,116
Closed -$290K – 4605
2021
Q2 		$290K Buy
+10,116
New +$360K ﹤0.01% 3538

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments's PRLD Position: Q1 2026 in Review

Two Sigma Investments increased its Prelude Therapeutics (PRLD) stake by 17% in Q1 2026, buying an estimated $354K and bringing the position to 923,626 shares worth $3.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2402.

Two Sigma Investments first reported a position in PRLD in Q2 2021 and has held it in 19 quarters since. The position peaked at $3.52M in Q4 2021. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Two Sigma Investments held 923,626 shares of Prelude Therapeutics worth $3.16M as of Q1 2026.
  • Two Sigma Investments bought 134,931 Prelude Therapeutics shares in Q1 2026, an estimated $354K.
  • Prelude Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #2402 holding.
  • Two Sigma Investments first reported a position in Prelude Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Two Sigma Investments's Prelude Therapeutics position peaked at $3.52M in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.